EGFR and non-small cell lung carcinoma: A sequent phase III FLAURA study assessed the efficacy and safety of osimertinib in patients with previously untreated EGFR mutated advanced NSCLC compared with the standard first-generation EGFR-TKIs (gefitinib or erlotinib) [39].